Celularity Inc. (NASDAQ:CELUW) Sees Large Growth in Short Interest
Celularity Inc. (NASDAQ:CELUW) Sees Large Growth in Short Interest
Celularity Inc. (NASDAQ:CELUW – Get Rating) was the recipient of a large growth in short interest in February. As of February 15th, there was short interest totalling 18,300 shares, a growth of 190.5% from the January 31st total of 6,300 shares. Based on an average daily volume of 14,200 shares, the short-interest ratio is currently 1.3 days.
Celularity Inc.（纳斯达克股票代码：CELUW — Get Rating）是2月份空头利率大幅增长的受益者。截至2月15日，空头利率共计18,300股，较1月31日的6,300股增长了190.5％。根据14,200股的平均每日成交量，目前空头利率为1.3天。
Celularity Stock Performance
Celularity 股票表现
Shares of Celularity stock opened at $0.08 on Wednesday. Celularity has a one year low of $0.06 and a one year high of $1.99. The firm has a 50-day moving average price of $0.09.
周三，Celularity的股票开盘价为0.08美元。Celularity创下了0.06美元的一年低点和1.99美元的一年高点。该公司的50天移动平均价格为0.09美元。
Celularity Company Profile
Celularity 公司简介
(Get Rating)
（获取评分）
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.
Celularity Inc是一家临床阶段的生物技术公司，开发现成的胎盘衍生异体细胞疗法，用于治疗癌症、免疫和传染病。它通过三个部分运作：细胞疗法、退行性疾病和生物银行。该公司的主要治疗项目包括 CYCART-19，一种胎盘衍生的 CAR-T 疗法，目前处于治疗 B 细胞恶性肿瘤的 I 期临床试验中；CYNK-001，胎盘衍生的未修饰自然杀伤细胞 (NK) 细胞，正在进行治疗急性髓系白血病的 I 期临床试验，以及治疗多形性胶质母细胞瘤和 COVID-19 的 I 期临床试验；CYNK-101 转基因 NK 细胞，正在进行治疗 HER2+ 胃癌和胃食管癌的 I 期临床试验；APPL-001，胎盘-衍生的间充质样粘附基质细胞，处于治疗克罗恩病的临床前阶段；以及 PDA-002，一种胎盘衍生的间充质样粘附基质细胞，处于治疗面部肩胛肌营养不良症的临床前阶段。
Featured Stories
精选故事
- Get a free copy of the StockNews.com research report on Celularity (CELUW)
- Will Q4 Results Send Zoom Video Stock Higher?
- Is Amazon a Blue Chip Stock?
- Occidental Petroleum Pulls Back To The Sweet Spot
- Should You Take a Cruise in Royal Caribbean Stock?
- Is Target Stock Aiming For A Breakout In 2023?
- 免费获取 StockNews.com 关于 Celularity (CELUW) 的研究报告
- 第四季度的业绩会让 Zoom Video 的股票走高吗？
- 亚马逊是蓝筹股吗？
- 西方石油公司回到了最佳位置
- 你应该乘皇家加勒比海游船吗？
- 目标股的目标是在 2023 年突破吗？
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Celularity Daily 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Celularity及相关公司的最新新闻和分析师评级的简明每日摘要。